Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations

Colquitt, Charlie and Jones, Jocelyn D. and Jackson, Sylvia H. (2014) Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations. Cardiology and Angiology: An International Journal, 2 (4). pp. 278-292. ISSN 2347520X

[thumbnail of Colquitt242014CA11319.pdf] Text
Colquitt242014CA11319.pdf - Published Version

Download (244kB)

Abstract

Atrial Fibrillation (AF) is the most common arrhythmia. AF is a major risk factor for stoke. Warfarin has been available for more than 60 years and until recently it was the only oral anticoagulant used for the prevention of stroke. Despite the extensive studies and proven efficacy, its utility is limited by multiple factors. Warfarin interacts with a multitude of drugs and foods, has a delayed onset of action, has a narrow therapeutic range, requires routine lab monitoring and exhibits variable responses in patients. The novel agents dabigatran, rivaroxaban and apixaban have the potential to have some of the limitations of warfarin. This article will discuss the pharmacokinetic and pharmacological considerations and different characteristics of the novel anticoagulants when used for the prevention of AF.

Item Type: Article
Subjects: AP Academic Press > Medical Science
Depositing User: Unnamed user with email support@apacademicpress.com
Date Deposited: 10 Jul 2023 05:13
Last Modified: 26 Jul 2024 06:37
URI: http://info.openarchivespress.com/id/eprint/1562

Actions (login required)

View Item
View Item